aminolevulinic acid has been researched along with Disease Exacerbation in 34 studies
Aminolevulinic Acid: A compound produced from succinyl-CoA and GLYCINE as an intermediate in heme synthesis. It is used as a PHOTOCHEMOTHERAPY for actinic KERATOSIS.
5-aminolevulinic acid : The simplest delta-amino acid in which the hydrogens at the gamma position are replaced by an oxo group. It is metabolised to protoporphyrin IX, a photoactive compound which accumulates in the skin. Used (in the form of the hydrochloride salt)in combination with blue light illumination for the treatment of minimally to moderately thick actinic keratosis of the face or scalp.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Introducing 5-aminolevulinic acid-photodynamic diagnosis into transurethral resection reduces residual bladder cancer and improves the cumulative intravesical recurrence-free survival in patients with non-muscle-invasive bladder cancer, indicating its possible therapeutic benefits." | 8.12 | Photodynamic diagnosis-assisted transurethral resection using oral 5-aminolevulinic acid decreases residual cancer and improves recurrence-free survival in patients with non-muscle-invasive bladder cancer. ( Harada, S; Honda, T; Kani, N; Kato, T; Matsuoka, Y; Okazoe, H; Sugimoto, M; Taoka, R; Tohi, Y; Tsunemori, H; Ueda, N; Yamasaki, M, 2022) |
| " Mild or moderate adverse effects were similar for both groups." | 6.87 | Effectiveness and safety of 0·5% colchicine cream vs. photodynamic therapy with methyl aminolaevulinate in the treatment of actinic keratosis and skin field cancerization of the forearms: a randomized controlled trial. ( Abbade, LPF; Ferreira, ER; Lima, TRR; Miola, AC; Miot, HA; Schmitt, JV, 2018) |
| "COL 0·5% cream and MAL-PDT are safe and effective for treating SFC." | 6.87 | Effectiveness and safety of 0·5% colchicine cream vs. photodynamic therapy with methyl aminolaevulinate in the treatment of actinic keratosis and skin field cancerization of the forearms: a randomized controlled trial. ( Abbade, LPF; Ferreira, ER; Lima, TRR; Miola, AC; Miot, HA; Schmitt, JV, 2018) |
| "5-aminolevulinic acid is a protoporphyrin IX precursor used for photodynamic diagnosis." | 5.72 | Photodynamic diagnosis-assisted transurethral resection using oral 5-aminolevulinic acid decreases residual cancer and improves recurrence-free survival in patients with non-muscle-invasive bladder cancer. ( Harada, S; Honda, T; Kani, N; Kato, T; Matsuoka, Y; Okazoe, H; Sugimoto, M; Taoka, R; Tohi, Y; Tsunemori, H; Ueda, N; Yamasaki, M, 2022) |
| " No severe adverse effects were reported." | 5.43 | Safety and Efficacy of 5-Aminolevulinic Acid for High Grade Glioma in Usual Clinical Practice: A Prospective Cohort Study. ( Arráez, MÁ; Garcia, R; González, JJ; Montané, E; Rimbau, J; Tardáguila, M; Teixidor, P; Vidal, X; Villalba, G, 2016) |
| "High-grade gliomas are aggressive, incurable tumors characterized by extensive diffuse invasion of the normal brain parenchyma." | 5.42 | A pilot cost-effectiveness analysis of treatments in newly diagnosed high-grade gliomas: the example of 5-aminolevulinic Acid compared with white-light surgery. ( Alves, M; Castel-Branco, M; Esteves, S; Stummer, W, 2015) |
| "Laser therapy appears the best option among nonsurgical approaches for actinic cheilitis, and PDT showed higher efficacy when sequentially combined with 5% imiquimod." | 5.05 | Treatments of actinic cheilitis: A systematic review of the literature. ( Cornacchia, L; Lai, M; Longo, C; Pampena, R; Pellacani, G; Peris, K, 2020) |
| "Introducing 5-aminolevulinic acid-photodynamic diagnosis into transurethral resection reduces residual bladder cancer and improves the cumulative intravesical recurrence-free survival in patients with non-muscle-invasive bladder cancer, indicating its possible therapeutic benefits." | 4.12 | Photodynamic diagnosis-assisted transurethral resection using oral 5-aminolevulinic acid decreases residual cancer and improves recurrence-free survival in patients with non-muscle-invasive bladder cancer. ( Harada, S; Honda, T; Kani, N; Kato, T; Matsuoka, Y; Okazoe, H; Sugimoto, M; Taoka, R; Tohi, Y; Tsunemori, H; Ueda, N; Yamasaki, M, 2022) |
| " Assessment of the VEGF-secreting activity of resistant colon cancer cells in different degree of malignancy: SW480 and SW620 under hypoxia-like conditions during δ- aminolevulinic acid (ALA) PDT was the objective of our study." | 3.88 | Secretion of the angiogenic factor VEGF after photodynamic therapy with ALA under hypoxia-like conditions in colon cancer cells. ( Czuba, ZP; Kawczyk-Krupka, A; Krammer, B; Kwiatek, B; Latos, W; Mertas, A; Sieroń, A; Verwanger, T, 2018) |
| "Week 52 lesion recurrence rates were 7." | 2.94 | A Randomized Trial of Broad Area ALA-PDT for Field Cancerization Mitigation in High-Risk Patients. ( Berg, JE; Ferdon, MB; Houlihan, A; Marcus, SL; Piacquadio, D, 2020) |
| " Mild or moderate adverse effects were similar for both groups." | 2.87 | Effectiveness and safety of 0·5% colchicine cream vs. photodynamic therapy with methyl aminolaevulinate in the treatment of actinic keratosis and skin field cancerization of the forearms: a randomized controlled trial. ( Abbade, LPF; Ferreira, ER; Lima, TRR; Miola, AC; Miot, HA; Schmitt, JV, 2018) |
| "COL 0·5% cream and MAL-PDT are safe and effective for treating SFC." | 2.87 | Effectiveness and safety of 0·5% colchicine cream vs. photodynamic therapy with methyl aminolaevulinate in the treatment of actinic keratosis and skin field cancerization of the forearms: a randomized controlled trial. ( Abbade, LPF; Ferreira, ER; Lima, TRR; Miola, AC; Miot, HA; Schmitt, JV, 2018) |
| "Non-muscle-invasive bladder cancer (NMIBC) is associated with a high recurrence risk, partly because of the persistence of lesions following transurethral resection of bladder tumour (TURBT) due to the presence of multiple lesions and the difficulty in identifying the exact extent and location of tumours using standard white-light cystoscopy (WLC)." | 2.50 | Clinical and cost effectiveness of hexaminolevulinate-guided blue-light cystoscopy: evidence review and updated expert recommendations. ( Babjuk, M; Gontero, P; Jacqmin, D; Karl, A; Kruck, S; Mariappan, P; Palou Redorta, J; Stenzl, A; van Velthoven, R; Witjes, JA; Zaak, D, 2014) |
| "5-aminolevulinic acid is a protoporphyrin IX precursor used for photodynamic diagnosis." | 1.72 | Photodynamic diagnosis-assisted transurethral resection using oral 5-aminolevulinic acid decreases residual cancer and improves recurrence-free survival in patients with non-muscle-invasive bladder cancer. ( Harada, S; Honda, T; Kani, N; Kato, T; Matsuoka, Y; Okazoe, H; Sugimoto, M; Taoka, R; Tohi, Y; Tsunemori, H; Ueda, N; Yamasaki, M, 2022) |
| "The challenge in the treatment of glioblastoma is the failure to identify the cancer invasive area outside the contrast-enhancing tumour which leads to the high local progression rate." | 1.56 | A Neural Network Approach to Identify the Peritumoral Invasive Areas in Glioblastoma Patients by Using MR Radiomics. ( Boonzaier, NR; Li, C; Matys, T; Price, SJ; van der Hoorn, A; Yan, JL, 2020) |
| "Currently, efficient regimens to reverse atherosclerotic plaques are not available in the clinic." | 1.51 | Rapid inhibition of atherosclerotic plaque progression by sonodynamic therapy. ( Cao, W; Cao, Z; Chen, X; Cheng, J; Gao, W; Guo, S; Jiang, Y; Li, B; Li, M; Li, Q; Li, X; Li, Z; Peng, C; Shen, J; Sun, J; Sun, X; Tian, F; Tian, Y; Tian, Z; Wang, H; Wang, P; Wang, T; Wang, W; Wang, Y; Yang, J; Yang, Y; Yao, J; Zhang, Z; Zhao, X; Zhou, Q, 2019) |
| "The shrunken atherosclerotic plaques displayed compositional alterations, with a reduction in lesional macrophages and lipids." | 1.51 | Rapid inhibition of atherosclerotic plaque progression by sonodynamic therapy. ( Cao, W; Cao, Z; Chen, X; Cheng, J; Gao, W; Guo, S; Jiang, Y; Li, B; Li, M; Li, Q; Li, X; Li, Z; Peng, C; Shen, J; Sun, J; Sun, X; Tian, F; Tian, Y; Tian, Z; Wang, H; Wang, P; Wang, T; Wang, W; Wang, Y; Yang, J; Yang, Y; Yao, J; Zhang, Z; Zhao, X; Zhou, Q, 2019) |
| "Human colorectal cancer cells of different malignant potential SW480 and SW620 were used in the experiment." | 1.46 | The effect of ALA-PDT under normoxia and cobalt chloride (CoCl ( Czuba, ZP; Kawczyk-Krupka, A; Krupka, M; Kwiatek, B; Kwiatek, S; Sieroń, K, 2017) |
| " No severe adverse effects were reported." | 1.43 | Safety and Efficacy of 5-Aminolevulinic Acid for High Grade Glioma in Usual Clinical Practice: A Prospective Cohort Study. ( Arráez, MÁ; Garcia, R; González, JJ; Montané, E; Rimbau, J; Tardáguila, M; Teixidor, P; Vidal, X; Villalba, G, 2016) |
| "High-grade gliomas are aggressive, incurable tumors characterized by extensive diffuse invasion of the normal brain parenchyma." | 1.42 | A pilot cost-effectiveness analysis of treatments in newly diagnosed high-grade gliomas: the example of 5-aminolevulinic Acid compared with white-light surgery. ( Alves, M; Castel-Branco, M; Esteves, S; Stummer, W, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (11.76) | 29.6817 |
| 2010's | 23 (67.65) | 24.3611 |
| 2020's | 7 (20.59) | 2.80 |
| Authors | Studies |
|---|---|
| Taoka, R | 1 |
| Matsuoka, Y | 1 |
| Yamasaki, M | 1 |
| Kani, N | 1 |
| Honda, T | 1 |
| Harada, S | 1 |
| Tohi, Y | 1 |
| Kato, T | 1 |
| Okazoe, H | 1 |
| Tsunemori, H | 1 |
| Ueda, N | 1 |
| Sugimoto, M | 1 |
| Lai, M | 1 |
| Pampena, R | 1 |
| Cornacchia, L | 1 |
| Pellacani, G | 1 |
| Peris, K | 1 |
| Longo, C | 1 |
| Pohar, KS | 1 |
| Piacquadio, D | 1 |
| Houlihan, A | 1 |
| Ferdon, MB | 1 |
| Berg, JE | 1 |
| Marcus, SL | 1 |
| Yan, JL | 1 |
| Li, C | 1 |
| van der Hoorn, A | 1 |
| Boonzaier, NR | 1 |
| Matys, T | 1 |
| Price, SJ | 1 |
| Cerovac, A | 1 |
| Brigic, A | 1 |
| Softic, D | 1 |
| Barakovic, A | 1 |
| Adzajlic, S | 1 |
| Lotan, Y | 1 |
| Chaplin, I | 1 |
| Ahmadi, H | 1 |
| Meng, X | 1 |
| Roberts, S | 1 |
| Ladi-Seyedian, S | 1 |
| Bagrodia, A | 1 |
| Margulis, V | 1 |
| Woldu, S | 1 |
| Daneshmand, S | 1 |
| Kawczyk-Krupka, A | 2 |
| Czuba, ZP | 2 |
| Kwiatek, B | 2 |
| Kwiatek, S | 1 |
| Krupka, M | 1 |
| Sieroń, K | 1 |
| Jacqmin, D | 2 |
| Jichlinski, P | 1 |
| Molinier, L | 1 |
| de la Taille, A | 1 |
| Irani, J | 1 |
| Malavaud, B | 1 |
| Mertas, A | 1 |
| Latos, W | 1 |
| Verwanger, T | 1 |
| Krammer, B | 1 |
| Sieroń, A | 1 |
| Kohoutova, D | 1 |
| Haidry, R | 2 |
| Banks, M | 1 |
| Butt, MA | 1 |
| Dunn, J | 1 |
| Thorpe, S | 2 |
| Lovat, L | 1 |
| Miola, AC | 1 |
| Ferreira, ER | 1 |
| Lima, TRR | 1 |
| Schmitt, JV | 1 |
| Abbade, LPF | 1 |
| Miot, HA | 1 |
| Sun, X | 1 |
| Guo, S | 1 |
| Yao, J | 1 |
| Wang, H | 1 |
| Peng, C | 1 |
| Li, B | 1 |
| Wang, Y | 1 |
| Jiang, Y | 1 |
| Wang, T | 1 |
| Yang, Y | 1 |
| Cheng, J | 1 |
| Wang, W | 1 |
| Cao, Z | 1 |
| Zhao, X | 1 |
| Li, X | 1 |
| Sun, J | 1 |
| Yang, J | 1 |
| Tian, F | 1 |
| Chen, X | 1 |
| Li, Q | 1 |
| Gao, W | 1 |
| Shen, J | 1 |
| Zhou, Q | 1 |
| Wang, P | 1 |
| Li, Z | 1 |
| Tian, Z | 1 |
| Zhang, Z | 1 |
| Cao, W | 1 |
| Li, M | 1 |
| Tian, Y | 1 |
| Jia, QN | 1 |
| Nguyen, GH | 1 |
| Fang, K | 1 |
| Jin, HZ | 1 |
| Zeng, YP | 1 |
| Reinhold, U | 1 |
| Petering, H | 1 |
| Dirschka, T | 1 |
| Rozsondai, A | 1 |
| Gille, J | 1 |
| Kurzen, H | 1 |
| Ostendorf, R | 1 |
| Ebeling, A | 1 |
| Stocker, M | 1 |
| Radny, P | 1 |
| Lee, PK | 1 |
| Kloser, A | 1 |
| Liang, WM | 1 |
| Theng, TS | 1 |
| Lim, KS | 1 |
| Tan, WP | 1 |
| Witjes, JA | 1 |
| Babjuk, M | 1 |
| Gontero, P | 1 |
| Karl, A | 1 |
| Kruck, S | 1 |
| Mariappan, P | 1 |
| Palou Redorta, J | 1 |
| Stenzl, A | 1 |
| van Velthoven, R | 1 |
| Zaak, D | 2 |
| Kamp, MA | 2 |
| Felsberg, J | 1 |
| Sadat, H | 1 |
| Kuzibaev, J | 1 |
| Steiger, HJ | 2 |
| Rapp, M | 2 |
| Reifenberger, G | 1 |
| Dibué, M | 1 |
| Sabel, M | 2 |
| Esteves, S | 1 |
| Alves, M | 1 |
| Castel-Branco, M | 1 |
| Stummer, W | 1 |
| Rose, JB | 1 |
| Armstrong, S | 1 |
| Hermann, GG | 1 |
| Kjellberg, J | 1 |
| Malmström, PU | 2 |
| Teixidor, P | 1 |
| Arráez, MÁ | 1 |
| Villalba, G | 1 |
| Garcia, R | 1 |
| Tardáguila, M | 1 |
| González, JJ | 1 |
| Rimbau, J | 1 |
| Vidal, X | 1 |
| Montané, E | 1 |
| Dansk, V | 1 |
| Bläckberg, M | 1 |
| Malmenäs, M | 1 |
| Fischer, I | 1 |
| Bühner, J | 1 |
| Turowski, B | 1 |
| Cornelius, JF | 1 |
| Slotty, PJ | 1 |
| Toda, M | 1 |
| Karen, JK | 1 |
| Hale, EK | 1 |
| Yeon, JH | 1 |
| Jung, JY | 1 |
| Choi, JW | 1 |
| Kim, BJ | 1 |
| Lee, JH | 1 |
| Youn, SW | 1 |
| Park, KC | 1 |
| Huh, CH | 1 |
| Geavlete, B | 1 |
| Multescu, R | 1 |
| Georgescu, D | 1 |
| Jecu, M | 1 |
| Stanescu, F | 1 |
| Geavlete, P | 1 |
| Surong, Z | 1 |
| Chuanyu, L | 1 |
| Shizheng, X | 1 |
| Alloo, A | 1 |
| Garibyan, L | 1 |
| LeBoeuf, N | 1 |
| Lin, G | 1 |
| Werchniak, A | 1 |
| Hodi, FS | 1 |
| Flaherty, KT | 1 |
| Lawrence, DP | 1 |
| Lin, JY | 1 |
| Dunn, JM | 1 |
| Mackenzie, GD | 1 |
| Banks, MR | 1 |
| Mosse, CA | 1 |
| Green, S | 1 |
| Rodriguez-Justo, M | 1 |
| Winstanley, A | 1 |
| Novelli, MR | 1 |
| Bown, SG | 1 |
| Lovat, LB | 1 |
| Jain, S | 1 |
| Kockelbergh, RC | 1 |
| Burger, M | 1 |
| Stief, CG | 1 |
| Filbeck, T | 1 |
| Wieland, WF | 1 |
| Roessler, W | 1 |
| Denzinger, S | 1 |
| Eljamel, MS | 1 |
| Goodman, C | 1 |
| Moseley, H | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| 5-Aminolevulinic Acid (5-ALA) Gliolan®: Usage Increase Proposal for Neurosurgical Procedures in High-Grade Gliomas[NCT05850377] | 90 participants (Anticipated) | Observational | 2023-06-01 | Not yet recruiting | |||
| A Single Center Phase II Trial of Vemurafenib (R05185426) in Poor Performance Status Patients With Unresectable Locally Advanced or Metastatic Melanoma Harboring a V600E/K Mutation[NCT01474551] | Phase 2 | 2 participants (Actual) | Interventional | 2011-11-30 | Terminated (stopped due to Lack of accrual) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 will be used to determine treatment response. In order to be considered evaluable for response, a patient must have completed at least 1 cycle of therapy. Patients who do not complete a cycle of therapy can be replaced. (NCT01474551)
Timeframe: 2 years
| Intervention | participants (Number) | |||
|---|---|---|---|---|
| Stable Disease | Complete Response | Partial Response | Progression of Disease | |
| Vemurafenib | 1 | 0 | 0 | 0 |
5 reviews available for aminolevulinic acid and Disease Exacerbation
| Article | Year |
|---|---|
Treatments of actinic cheilitis: A systematic review of the literature.
Topics: Aminolevulinic Acid; Carcinoma, Squamous Cell; Cheilitis; Combined Modality Therapy; Dermabrasion; D | 2020 |
Blue Light Cystoscopy: Indications and Outcomes.
Topics: Administration, Intravesical; Aminolevulinic Acid; Cystoscopy; Disease Progression; Humans; Light; N | 2020 |
Current methods for photodynamic therapy in the US: comparison of MAL/PDT and ALA/PDT.
Topics: Aminolevulinic Acid; Carcinoma, Squamous Cell; Disease Progression; Humans; Keratosis, Actinic; Phot | 2013 |
Clinical and cost effectiveness of hexaminolevulinate-guided blue-light cystoscopy: evidence review and updated expert recommendations.
Topics: Aminolevulinic Acid; Cost-Benefit Analysis; Cystectomy; Cystoscopy; Disease Progression; Disease-Fre | 2014 |
The role of photodynamic diagnosis in the contemporary management of superficial bladder cancer.
Topics: Aminolevulinic Acid; Anthracenes; Antineoplastic Agents; Carcinoma, Transitional Cell; Cystoscopy; D | 2005 |
8 trials available for aminolevulinic acid and Disease Exacerbation
| Article | Year |
|---|---|
A Randomized Trial of Broad Area ALA-PDT for Field Cancerization Mitigation in High-Risk Patients.
Topics: Aged; Aminolevulinic Acid; Combined Modality Therapy; Cryotherapy; Disease Progression; Female; Huma | 2020 |
Long-term outcomes of the randomized controlled trial comparing 5-aminolaevulinic acid and Photofrin photodynamic therapy for Barrett's oesophagus related neoplasia.
Topics: Adenocarcinoma; Adult; Aged; Aminolevulinic Acid; Barrett Esophagus; Catheter Ablation; Dihematoporp | 2018 |
Effectiveness and safety of 0·5% colchicine cream vs. photodynamic therapy with methyl aminolaevulinate in the treatment of actinic keratosis and skin field cancerization of the forearms: a randomized controlled trial.
Topics: Aged; Aminolevulinic Acid; Atrophy; Biopsy; Carcinoma, Squamous Cell; Colchicine; Disease Progressio | 2018 |
Treatment changes and long-term recurrence rates after hexaminolevulinate (HAL) fluorescence cystoscopy: does it really make a difference in patients with non-muscle-invasive bladder cancer (NMIBC)?
Topics: Adult; Aged; Aged, 80 and over; Aminolevulinic Acid; Contrast Media; Cystoscopy; Disease Progression | 2012 |
Photodynamic therapy for multiple eruptive keratoacanthomas associated with vemurafenib treatment for metastatic melanoma.
Topics: Aged; Aminolevulinic Acid; Antineoplastic Agents; Carcinoma, Squamous Cell; Disease Progression; Dru | 2012 |
A randomised controlled trial of ALA vs. Photofrin photodynamic therapy for high-grade dysplasia arising in Barrett's oesophagus.
Topics: Adenocarcinoma; Aged; Aminolevulinic Acid; Barrett Esophagus; Dihematoporphyrin Ether; Disease Progr | 2013 |
Photodynamic diagnostics and noninvasive bladder cancer: is it cost-effective in long-term application? A Germany-based cost analysis.
Topics: Administration, Intravesical; Adult; Aged; Aged, 80 and over; Aminolevulinic Acid; Cost-Benefit Anal | 2007 |
ALA and Photofrin fluorescence-guided resection and repetitive PDT in glioblastoma multiforme: a single centre Phase III randomised controlled trial.
Topics: Aminolevulinic Acid; Dihematoporphyrin Ether; Disease Progression; Female; Glioblastoma; Humans; Kar | 2008 |
21 other studies available for aminolevulinic acid and Disease Exacerbation
| Article | Year |
|---|---|
Photodynamic diagnosis-assisted transurethral resection using oral 5-aminolevulinic acid decreases residual cancer and improves recurrence-free survival in patients with non-muscle-invasive bladder cancer.
Topics: Aminolevulinic Acid; Disease Progression; Humans; Neoplasm Recurrence, Local; Neoplasm, Residual; Ph | 2022 |
A Neural Network Approach to Identify the Peritumoral Invasive Areas in Glioblastoma Patients by Using MR Radiomics.
Topics: Adult; Aged; Aminolevulinic Acid; Brain Neoplasms; Cohort Studies; Contrast Media; Diffusion Magneti | 2020 |
Uncontrolled Acute Intermittent Porphyria as a Cause of Spontaneous Abortion.
Topics: Abortion, Spontaneous; Adult; Aminolevulinic Acid; Contraceptives, Oral, Hormonal; Disease Progressi | 2020 |
Prospective evaluation of blue-light flexible cystoscopy with hexaminolevulinate in non-muscle-invasive bladder cancer.
Topics: Aged; Aged, 80 and over; Aminolevulinic Acid; Biopsy; Color; Cystoscopy; Disease Progression; Female | 2021 |
The effect of ALA-PDT under normoxia and cobalt chloride (CoCl
Topics: Aminolevulinic Acid; Apoptosis; Cell Adhesion Molecules; Cell Count; Cell Line, Tumor; Cell Survival | 2017 |
Observational Studies Requested by European Health Authorities: Governmental Interference or an Enhancement of Everyday Urological Practice? The Hexvix® Observational Patients Evaluation Study as an Example of What to Expect.
Topics: Adult; Aged; Aged, 80 and over; Aminolevulinic Acid; Cystectomy; Cystoscopy; Disease Progression; Di | 2017 |
Secretion of the angiogenic factor VEGF after photodynamic therapy with ALA under hypoxia-like conditions in colon cancer cells.
Topics: Aminolevulinic Acid; Apoptosis; Cell Line, Tumor; Cell Survival; Colonic Neoplasms; Disease Progress | 2018 |
Rapid inhibition of atherosclerotic plaque progression by sonodynamic therapy.
Topics: Aminolevulinic Acid; Animals; Aortic Diseases; Apoptosis; Atorvastatin; Carotid Artery Diseases; Cel | 2019 |
Development of squamous cell carcinoma from erythroplasia of Queyrat following photodynamic therapy.
Topics: Aged; Aminolevulinic Acid; Carcinoma, Squamous Cell; Disease Progression; Erythroplasia; Humans; Mal | 2018 |
Photodynamic therapy with a 5-ALA patch does not increase the risk of conversion of actinic keratoses into squamous cell carcinoma: Results of a multicentre non-interventional study.
Topics: Aminolevulinic Acid; Carcinoma, Squamous Cell; Disease Progression; DNA Damage; Humans; Keratosis, A | 2018 |
Rapid development of squamous cell carcinoma after photodynamic therapy.
Topics: Aged; Aminolevulinic Acid; Bowen's Disease; Carcinoma, Squamous Cell; Disease Progression; Facial Ne | 2014 |
5-ALA-induced fluorescence behavior of reactive tissue changes following glioblastoma treatment with radiation and chemotherapy.
Topics: Aged; Aminolevulinic Acid; Brain Neoplasms; Disease Progression; Female; Fluorescence; Glioblastoma; | 2015 |
A pilot cost-effectiveness analysis of treatments in newly diagnosed high-grade gliomas: the example of 5-aminolevulinic Acid compared with white-light surgery.
Topics: Adult; Aged; Aminolevulinic Acid; Brain Neoplasms; Cost-Benefit Analysis; Disease Progression; Femal | 2015 |
Budget impact of incorporating one instillation of hexaminolevulinate hydrochloride blue-light cytoscopy in transurethral bladder tumour resection for patients with non-muscle-invasive bladder cancer in Sweden.
Topics: Aminolevulinic Acid; Budgets; Costs and Cost Analysis; Cystoscopy; Disease Progression; Humans; Neop | 2016 |
Safety and Efficacy of 5-Aminolevulinic Acid for High Grade Glioma in Usual Clinical Practice: A Prospective Cohort Study.
Topics: Adult; Aged; Aminolevulinic Acid; Brain Neoplasms; Cohort Studies; Disease Progression; Disease-Free | 2016 |
Hexaminolevulinate hydrochloride blue-light flexible cystoscopy in the detection and follow-up of nonmuscle-invasive bladder cancer: cost consequences during outpatient surveillance in Sweden.
Topics: Aminolevulinic Acid; Costs and Cost Analysis; Cystectomy; Cystoscopy; Disease Progression; Follow-Up | 2016 |
5-ALA fluorescence of cerebral metastases and its impact for the local-in-brain progression.
Topics: Adult; Aged; Aged, 80 and over; Aminolevulinic Acid; Brain; Brain Neoplasms; Disease Progression; Fe | 2016 |
Intraoperative navigation and fluorescence imagings in malignant glioma surgery.
Topics: Aminolevulinic Acid; Brain; Brain Neoplasms; Disease Progression; Equipment Design; Fluorescent Dyes | 2008 |
Rapid progression of a basal cell carcinoma after photodynamic therapy.
Topics: Aminolevulinic Acid; Biopsy; Carcinoma, Basal Cell; Disease Progression; Humans; Keratosis, Actinic; | 2010 |
Keratoacanthoma aggravated after photodynamic therapy.
Topics: Aminolevulinic Acid; Disease Progression; Humans; Keratoacanthoma; Male; Middle Aged; Nose Neoplasms | 2010 |
Experimental study of δ-ALA-PDT in the treatment in BXSB lupus-prone mice.
Topics: Aminolevulinic Acid; Animals; Antibodies, Antinuclear; Disease Progression; Immune Complex Diseases; | 2011 |